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Calreticulin is recognized as one of the pivotal damage-associated molecular pattern mole-
cules alerting the host of the presence of distressed cells. In this role, calreticulin becomes
exposed on the surface of tumor cells treated by several types of cancer therapy including
photodynamic therapy (PDT). The goal of the present study was to examine the poten-
tial of externally added calreticulin for augmenting antitumor effect mediated by PDT.
Recombinant calreticulin was found to bind to mouse SCCVII tumor cells treated by PDT.
Compared to the outcome with PDT alone, cure rates of SCCVII tumors grown in immuno-
competent C3H/HeN mice were elevated when calreticulin (0.4 mg/mouse) was injected
peritumorally immediately after PDT. Such therapeutic gain with PDT plus calreticulin com-
bination was not obtained with SCCVII tumors growing in immunodeficient NOD-scid mice.
In PDT-vaccine protocol, where PDT-treated SCCVII cells are used for vaccination of SCCVII
tumor-bearing mice, adding recombinant calreticulin to cells before their injection produced
improved therapeutic effect.The expression of calreticulin gene was reduced in PDT-treated
cells, while no changes were observed with the expression of this gene in tumor, liver,
and spleen tissues in PDT-vaccine-treated mice.These findings reveal that externally added
recombinant calreticulin can boost antitumor response elicited by PDT or PDT-generated
vaccines, and can thus serve as an effective adjuvant for cancer treatment with PDT and
probably other cancer cell stress-inducing modalities.
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INTRODUCTION
Calreticulin is primarily ER-residing chaperone protein with a
broad array of cellular functions, including maintenance of ade-
quate calcium levels, protein folding and trafficking, gene tran-
scription regulation, cell adherence and migration, apoptosis and
dead cell clearance, and immune responses (1, 2). Cancer therapy-
mediated lethal insults that involve stress induction in the ER
induce the translocation of calreticulin to the outer leaflet of
the plasma membrane by an active process occurring before
the appearance of morphological signs of apoptosis (3, 4). Such
surface-exposed calreticulin serves as a powerful mobilizing signal
to the immune system, which has inspired recognition of calreti-
culin as one of the most important damage-associated molecular
patterns (DAMPs) (5). As danger signals,DAMPs alert the host that
immune response is required to restore homeostasis (3, 6). Sur-
face calreticulin expression on dying cancer cells is critical for their
demise by immunological cell death (ICD) resulting in immune
rejection of tumors with the same cells (7).
Photodynamic therapy (PDT) belongs to cancer modalities
capable of inducing an abundance of DAMPs including surface-
exposed calreticulin (5, 8). This therapy is established clinically
for treatment of various malignant and non-oncological lesions
(9). It works by localized generation of reactive oxygen species
mediated by the transfer of energy absorbed by light-activated
drugs (photosensitizers) to molecular oxygen (10, 11). Photoox-
idative lesions induced in PDT-treated cells provoke a strong
oxidative stress that with many photosensitizers includes the ER.
Such a type of stress was suggested to lead to the escape of cal-
reticulin and other ER molecules to the cell surface (4). Ceramide
and sphingosine-1-phosphate are ER-derived molecules that were
likewise found exposed on the surface of PDT-treated cells and
were also shown to act as DAMPs (12, 13). With PDT medi-
ated by photosensitizer chlorin e6 (ce6), we detected cell surface-
exposed calreticulin as early as 15 min post-treatment (Korbelik,
unpublished).
Abundant engagement after PDT of various DAMPs, both
cancer cell surface expressed and released from treated cells was
suggested as one of the key elements responsible for the capacity
of this modality to elicit a strong immune response against treated
tumor (14). This PDT-induced antitumor-immune response can
be enhanced by a variety of immunostimulating treatments for
achieving superior tumor cures (15). The present report describes
how such approach can include recombinant calreticulin pro-
tein. The research questions to be addressed were: first, can the
recombinant calreticulin be used as an effective adjuvant to PDT
and/or PDT-generated vaccine therapy? Second, what investigative
directives should be followed when designing research for the com-
prehensive elucidation of the underlying mechanism of action?
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MATERIALS AND METHODS
TUMOR MODEL
The squamous cell carcinoma model SCCVII syngeneic to
C3H/HeN mice, a recognized model of head and neck cancer of
spontaneous origin with absence of strong immunogenicity (16),
was implanted subcutaneously into lower dorsal site of 7–9-week-
old C3H/HeN or NOD-scid mice. The tumors were treated with
PDT vaccine when they reached 5 mm and with PDT in situ at
7–8 mm size in largest diameter. The procedures used with mice
were in compliance with the protocols approved by the Animal
Care Committee of the University of British Columbia. Cultures of
SCCVII cells were maintained in alpha minimal essential medium
supplemented with 10% fetal bovine serum (Life Technologies,
Burlington, ON, Canada).
PREPARATION OF RECOMBINANT HUMAN CALRETICULIN
Native recombinant human calreticulin was generated using yeast
as expression host based on the methodology developed in pre-
vious work (17, 18). Whole coding sequence of human calreti-
culin gene (GenBank accession no. M84739) was PCR-cloned
from human adult liver cDNA library (Clontech Laboratories,
Saint-Germain-en-Laye, France) using primers that generate XbaI
restriction sites. The PCR product was digested and cloned
into the XmaJI site of pPIC3.5K shuttle vector (Invitrogen, Life
Technologies) under control of Pichia pastoris AOX1 promoter.
The pPIC3.5K-CRT plasmid was transformed into P. pastoris
GS115 (his4) (Invitrogen) by electroporation after linearization
with BglII restriction endonuclease. Several multi-copy integrants
grown on various geneticin concentrations were screened for
secretion of human calreticulin. Recombinant P. pastoris strain
(GS115:hCRT) with the optimal secretion of human calreticulin
was chosen for further studies. It was initially grown in the Ygly
medium (2% peptone from soybean, 1% yeast extract, 1% glycerin,
2× 10−5% biotin). After 24 h incubation, the cells were trans-
ferred into Ymet medium (2% peptone from soybean, 1% yeast
extract, 1% methanol, 2× 10−5% biotin) and incubated for 120 h,
with 1% methanol supplanted every 8 h. Following this induction
period, cells were separated from the medium by centrifugation
at 10,000 g for 20 min. Yeast growth medium was subjected to
prefiltration and microfiltration through filters with pore size of
1.6, 0.45, and 0.2µM (cat. nos. FT-3-1101-047, 15406-47 and
15407-47-MIN, respectively, SartoriusStedim Biotech, Goettingen,
Germany). After microfiltration, proteins were concentrated and
transferred into the binding buffer (20 mM l-histidine, pH 5.5,
100 mM NaCl) through tangential ultrafiltration using cassettes
with 100 kDa cut-off membranes (cat. no.VF20P3, SartoriusSte-
dim Biotech). Protein sample was loaded onto the Q Sepharose
FastFlow column (cat. no. 17-0510-10, GE Healthcare, Freiburg,
Germany). Unbound proteins were washed from the column with
10 column volumes of binding buffer, while bound proteins were
eluted with 15 column volumes NaCl gradient (100–500 mM). In
the final step, the elution fractions were analyzed by SDS-PAGE,
and the fractions showing≥ 90% pure human calreticulin were
pooled and dialyzed against storage buffer (20 mM Tris-HCl, pH
7.5, 100 mM NaCl, 3 mM CaCl2). The SDS-PAGE gel with the
final calreticulin preparation used in the experiments with cells
and in vivo is shown in Figure 2.
PDT AND PDT-VACCINE TREATMENT
Two different treatments involving photosensitizing drug expo-
sure followed by light application were performed using pho-
tosensitizers Temoporfin for PDT and chlorin e6 (ce6) for PDT
vaccines in standard doses established in previous extensive inves-
tigations. The protocol used for PDT-generated vaccine treatment
was described in detail earlier (19, 20). Briefly, for each treat-
ment group (6 mice), 1.2× 108 SCCVII cells were exposed to
ce6 (purchased from Frontier Scientific Inc., Logan, UT, USA) for
30 min at 0.5µg/ml followed by 1 J/cm2 of 665± 10 nm light. The
light, delivered through a liquid light guide (model 77638, Oriel
Instruments, Stratford, CT, USA), was produced by a 150 W QTH
lamp-based high-throughput source with an integrated ellipsoid
reflector and interchangeable interference filters (model FB-QTH-
3, Sciencetech Inc., London, ON, Canada). This PDT treatment
was lethal for around 70% of cells, most of them dying by apop-
tosis. After PDT treatment, the cells were left overnight (16 h)
at 37°C in EX-CELL chemically defined protein- and serum-free
medium (Sigma Chemical Co., St. Louis, MO, USA). The cells
were then collected, concentrated by centrifugation for treatment
with X-rays (60 Gy) followed in some treatment groups by the
exposure to recombinant rabbit calreticulin (Abcam Inc., Cam-
bridge, MA, USA) at the concentration of 15µg per vaccine dose
for 30 min on ice. The vaccine cells were then used immediately
for peritumoral injection (2× 107 per mouse). As a part of the
routine PDT-vaccine protocol, mice received low-dose cyclophos-
phamide (50 mg/kg i.p.) 24 h before vaccination (for controlling
immunoregulatory cell activity). The therapeutic effect of PDT
vaccines was assessed by monitoring changes in tumor size.
For PDT treatment of SCCVII tumors, the host mice were
administered Temoporfin (active pharmaceutical ingredient of
Foscan, provided by Biolitec Research GmbH, Jena, Germany) at
the dose of 0.1 mg/kg i.p., and 24 h later, the tumors were exposed
superficially to 655± 10 nm light (using the source described
above) with a dose rate of 80–90 mW/cm2 while the mice were
immobilized in specially designed holders. The mice were subse-
quently monitored for tumor growth and those showing no sign
of palpable tumor at 90 days post-treatment qualified as cured. For
testing the effect of PDT plus calreticulin combination,each mouse
was injected peritumorally 400µg of recombinant human calreti-
culin contained in 0.1 ml PBS immediately after photodynamic
light treatment.
CALRETICULIN ASSOCIATION WITH PDT-TREATED CELLS
The protocol was identical as used with the PDT-generated vac-
cine (exposure of SCCVII cells to ce6-based PDT followed by 16 h
post-incubation and then 30 min exposure to calreticulin on ice),
except that the recombinant human calreticulin was used and its
concentration was 20µg per million cells. In one treatment group,
mitoxantrone (M6545, Sigma) 0.5µg/ml was present during the
16-h post-incubation period. Presence of calreticulin on the sur-
face of SCCVII cells was assessed by staining the cells with chicken
polyclonal antibody to calreticulin (reactive with both human and
mouse protein) followed by Alexa Fluor 488-conjugated goat anti-
chicken IgY both purchased from Abcam. For isotype control,
ChromPure chicken IgY (Jackson ImmunoResearch Laborato-
ries, West Grove, PA, USA) was used as the primary antibody.
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Suspensions of stained cells were then analyzed by flow cytom-
etry performed on Coulter Epics Elite ESP (Coulter Electronics,
Hialeah, FL, USA) with 20,000 cells measured in each test. Flu-
orescence values per cell obtained with the isotype control were
deducted from values recorded with the calreticulin antibody.
CALRETICULIN GENE EXPRESSION ANALYSIS
Total RNA was extracted from SCCVII cells or mice tissues
using Trizol and cleaned up with Qiagen MinElute (Qiagen
Canada Inc., Montreal QC, Canada). It served for performing
gene expression analysis as described in detail in our previous
reports (20, 21). Briefly, the extracted total RNA was used for
creating complementary strand DNA transcript that was then
amplified by quantitative RT-PCR in the presence of mouse
calreticulin gene (NCBI Reference Sequence NM_007591.3)-
specific primers CTGAATACAAGGGCGAGTGGA (forward) and
GCATCGGGGGAGTATTCAGG (reverse) that were designed and
tested in our laboratory. The expression of housekeeping gene
glycerladehide-3-phosphate dehydrogenase (GAPDH) was also
measured and used for normalizing the expression of calretic-
ulin gene.
STATISTICAL ANALYSIS
Each experiment was repeated at least once. Statistical evaluation
of tumor response to PDT or PDT-vaccine treatment was done
using log-rank test, while the analysis of other data was based on
Mann–Whitney test with the threshold for statistical significance
set at 5%.
RESULTS
The PDT-generated vaccine protocol with SCCVII tumor model
developed in our laboratory, centers on preparing single-cell can-
cer vaccines by using in vitro PDT-treated SCCVII cells post-
incubated in culture for 16 h and then injected peritumorally
into mice bearing SCCVII tumors (19). To determine whether
the efficacy of PDT vaccine can be affected by modifying cal-
reticulin involvement, before injecting them to mice the vaccine
cells were altered either by 30 min exposure to calreticulin protein
or by treatment with mitoxantrone (known to induce cell sur-
face expression of calreticulin (22). The results are presented in
Figure 1. Compared to untreated SCCVII tumors, PDT vaccine
alone treatment produced a significant retardation in the growth
rate of these relatively fast growing tumors. This therapeutic gain
was further improved by both adjuvant calreticulin (15µg per
dose) and the exposure to mitoxantrone during the post-PDT
incubation of vaccine cells (Figure 1). Thus, the time for all the
tumors to reach the critical size of 200 mm3 was extended from
10 to 27 days. The same calreticulin dose per mouse was used by
Obeid et al. (22). Using the vaccine SCCVII cells treated with cal-
reticulin or mitoxantrone alone without PDT had no significant
impact on tumor growth rates compared to those with untreated
tumors (not shown).
The finding that calreticulin can act as an effective adju-
vant to PDT vaccine encouraged our further investigation for
which we secured required quantities of recombinant calretic-
ulin by developing its production from yeast carrying human
calreticulin gene. The SDS-PAGE gel with the final calreticulin
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FIGURE 1 |The impact of calreticulin exposure or mitoxantrone
treatment on the potency of PDT-generated vaccine. PDT vaccine was
prepared by treating SCCVII cells with ce6-PDT (30 min exposure to
0.5µg/ml ce6 followed by 1 J/cm2 of 665±10 nm light) and leaving them in
culture for 16 h post-treatment incubation before they were injected (20
million/mouse) peritumorally into C3H/HeN mice bearing SCCVII tumors.
With one treatment group, mitoxantrone (0.5µg/ml) was present during the
post-treatment incubation. Before injection, vaccine cells for one group of
mice were exposed to recombinant rabbit calreticulin (15µg per 20 million
cells) for 30 min on ice. For other details of PDT vaccine protocol, Section
“Materials and Methods.” Each treatment group consisted of 6 mice. The
response, based on two experiments, of SCCVII tumors to vaccine
treatment is depicted as changes in the percentage of mice with tumors
smaller than 200 mm3 in time after therapy. Statistically significant
difference (p<0.05): untreated vs. vaccine alone groups, vaccine alone vs.
vaccine with calreticulin groups, and vaccine vs. vaccine with mitoxantrone.
preparation used in the experiments with cells and in vivo is
shown in Figure 2. This allowed us to examine the effects of
calreticulin on the response of tumors treated in situ by PDT.
For this study, SCCVII tumors were implanted subcutaneously
either into immunocompetent syngeneic C3H/HeN mice or into
immunodeficient NOD-scid mice. When tumors reached 7–8 mm
in largest diameter, the mice were administered photosensitizer
Temoporfin, and 24 h later, the tumors were exposed to PDT
illumination. Since recombinant human calreticulin was admin-
istered directly into mice immediately after light treatment, its
dose was escalated to 400µg per injection. All PDT-treated
tumors became impalpable and necrotic within 24 h but recur-
rence was detected with many mice within 2 weeks post-therapy.
The results with immunocompetent mice (Figure 3A) showed
that the adjuvant calreticulin treatment rendered a significant
improvement in tumor response to PDT from marginally cura-
tive to the solid levels of about 40% cure rates. There was no
evidence with PDT-treated tumors of any effect following per-
itumoral injection of the same volume of saline (not shown).
No significant effect on tumor was observed following treatment
with calreticulin alone. In immunodeficient mice, the adjuvant cal-
reticulin was not effective in improving tumor response to PDT
(Figure 3B) and again no effect was observed with calreticulin
alone.
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FIGURE 2 | SDS-PAGE gel with human calreticulin protein purified
from yeast culture medium. The gel was loaded with 2.5 and 5µg of
human calreticulin and 1–5µg of BSA (cat. no. B14, Thermo Fisher
Scientific, Waltham, MA, USA) as amount control. M – Unstained protein
ladder (cat. no. 26614, Thermo Fisher Scientific).
One of the proteins sharing with calreticulin the capacity to
act as DAMP is heat shock protein 70 (Hsp70) (5, 23). We have
shown that externally supplied Hsp70 protein binds to tumor cells
that have sustained oxidative stress mediated by PDT (24). To
test whether a similar property is exhibited by calreticulin, mouse
tumor SCCVII cells were treated in vitro by PDT using photo-
sensitizer ce6. After 16-h post-PDT culture at 37°C, the cells were
transferred on ice and further incubated 30 min with recombinant
human calreticulin added to the medium. The calreticulin dose
range was 1–20µg per106 cells, i.e., similar to the levels described
for in vitro experiments by Obeid et al. (22). The cells were then
stained with anti-calreticulin antibody for detecting the presence
of this protein on the surface of cells using flow cytometry. The
results show that the calreticulin protein present in the medium
binds to PDT-treated cells but not to untreated cells (Figure 4).
As shown before (8, 12), PDT treatment induced the presentation
of endogenous calreticulin on the surface of cells. However, the
calreticulin levels on these cells were significantly greater when
in contact with the externally added calreticulin. Binding of this
protein to PDT-treated cells could not be detected when less than
1µg per million cells was added to the medium (not shown).
Another characteristic of Hsp70 is that its gene becomes upreg-
ulated not only in tumor cells directly treated by PDT but also
in the livers and spleens of mice with PDT-treated or PDT
vaccine-treated tumors (20, 24). In contrast, the expression of
gene encoding calreticulin decreased in SCCVII cells treated by
PDT (Figure 5A). The effect was PDT dose dependent, with close
to 50% reduction found in cells 3 h after they received the medium
tested PDT dose that attains around 90% cell kill. In vivo, no sig-
nificant differences were found in the calreticulin gene expression
in tumor, liver, and spleen tissues between untreated and PDT
vaccine-treated mice (Figure 5B).
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FIGURE 3 |The effect of tumor-localized calreticulin injection on PDT
response of SCCVII tumors growing in immunocompetent or
immunodeficient mice. The tumors growing either in (A) syngeneic
immunocompetent mice (C3H/HeN) or (B) in immunodeficient mice
(NOD-scid) were treated by Temoporfin-PDT (0.1 mg/kg i.p. Temoporfin
followed 24 h later by 80 J/cm2 light dose). Recombinant human calreticulin
(400µg/mouse) was injected peritumorally immediately after PDT light.
Mice were then monitored for up to 90 days for signs of tumor regrowth.
Each treatment group consisted of 8 mice. With C3H/HeN mice, the
response of PDT alone and PDT plus calreticulin groups were statistically
different (p<0.05).
DISCUSSION
In one of the earliest reports on the therapy-induced transloca-
tion of calreticulin to the surface of tumor cells and its relevance,
Obeid et al. (22) demonstrated that anthracyclines or their analog
mitoxantrone are effective in achieving an such effect and that this
is responsible for ICD produced by these drugs. In the same work,
the authors showed that tumor cells treated by a chemotherapy
agent mitoxantrone not only translocated intracellular calretic-
ulin to their surface but were also able to bind externally added
calreticulin protein. In accordance to these findings, our previous
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FIGURE 4 | Calreticulin binds to PDT-treated cells. The treatment of
SCCVII cells with ce6-PDT and 16-h post-incubation was performed using
the protocol for PDT vaccine preparation described in Figure 1. The cells
were then concentrated by centrifugation and kept on ice in the presence
of recombinant human calreticulin (20µg per million cells). Cell
suspensions were then stained with chicken antibody raised against
calreticulin or with isotype control immunoglobulin, followed by Alexa Fluor
488-conjugated secondary antibody, and analyzed by flow cytometry. The
data show the levels of cell surface-localized calreticulin on untreated and
PDT-treated cells that were either unexposed or exposed to recombinant
calreticulin. N =4, bars are SD, *statistically significant difference (p<0.05)
compared to calreticulin unexposed PDT-treated cells.
investigation revealed the induction of surface calreticulin expres-
sion on SCCVII cells treated with this neoplastic agent as well
as with PDT mediated by photosensitizer Photofrin (12), while
the present study shows that calreticulin protein present in cell
medium has no detectable affinity for binding to untreated cells
but associates readily with PDT-treated tumor cells.
Our results demonstrate that this association with externally
provided calreticulin renders PDT-vaccine cells therapeutically
more potent (Figure 1). The similar benefit can be obtained by
treating PDT-vaccine cells with mitoxantrone, which will further
raise surface calreticulin levels originally prompted to emerge by
PDT treatment. In the protocols for PDT of tumors in situ, the
therapeutic gain seen with adjuvant calreticulin (Figure 3) can be
expected to result from the association of this protein with cancer
cells upon its administration by tumor-localized injection. Impor-
tantly, such therapeutic gain was not produced with the host mice
deficient in mature lymphocytes (NOD-scid).
The capacity for binding to the surface of stressed tumor cells
such as those treated by PDT calreticulin shares with another
molecular chaperon and DAMP, hsp70 (24). Indeed, both of them
could be binding to their common receptor CD91 on macrophages
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FIGURE 5 | Expression of calreticulin gene in PDT-treated cells and
tumor, liver, and spleen tissues of mice bearing PDT-treated SCCVII
tumors. In experiments in vitro (A) SCCVII cells were exposed to
Temoporfin (0.1, 0.2, or 0.4µg/ml for 24 h) and then treated with
655±10 nm light (1 J/cm2). The cells were collected 3 h after PDT and their
total RNA isolated. In experiments in vivo (B) C3H/HeN mice with SCCVII
tumors received tumor-localized PDT vaccine treatment as described for
Figure 1. The mice were sacrificed 4 h later and their tumor, liver, and
spleen tissues collected for total RNA isolation. The obtained total RNA
samples were used for quantitative RT-PCR-based analysis of the
expression of calreticulin gene. The results are presented as
GAPDH-normalized mouse calreticulin gene expression relative to the same
feature in untreated cells or in the same tissue of untreated tumor-bearing
mice. N =4, bars are SD, *statistically significant difference (p< 0.05)
compared to calreticulin gene expression in PDT-untreated cells.
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(25) but the identity of their binding partner on the surface of
stressed tumor cells is not clear. Nonetheless, there are important
differences between calreticulin and Hsp70. Unlike with calretic-
ulin, tumor-localized recombinant Hsp70 protein injection after
PDT has no impact on therapy outcome (Korbelik, unpublished
results). On the other hand, as shown in Figure 5, calreticulin does
not share with Hsp70 the capacity for gene expression and pro-
duction to be upregulated in PDT-treated cells and be mobilized
systemically as acute phase reactant, as evidenced by the upreg-
ulation of Hsp70 gene in the liver and spleen of mice bearing
PDT-treated or a PDT vaccine-treated tumor (20, 24). Since the
primary function of Hsp70 is expediting the repair or elimination
of damaged intracellular proteins within stressed cells, it can be
assumed that the cells will upgrade its gene while trying to survive.
In contrast, the function of surface-exposed calreticulin is to facil-
itate the disposal of the cells doomed not to survive; in these cells,
sufficient calreticulin can be supplied from the existing intracellu-
lar locations. This is in conformity with the finding that the surface
exposure of calreticulin is entirely regulated in the cytoplasm by
post-transcriptional and/or post-translational processes (22).
Calreticulin accumulated on the surface of tumor cells may
modulate their death. Unlike Hsp70, which has inhibitory role in
cell death pathways (26), the role of calreticulin is controversial
due to reports suggesting its protection against apoptotic stimuli
while other evidence infers its participation in the cell death path-
way (4). The facts that tumor cells decorated with calreticulin are
more efficiently phagocytosed by dendritic cells and have increased
immunogenicity (22) are more consistent with the role of calretic-
ulin as promoter of their death and disposal. Since surface-exposed
calreticulin is one of the three DAMPs (together with ATP and
HMGB1) attributed a key role in the immunogenic potential of
ICD inducers (7), it seems rational to expect that its adjuvant prop-
erties described in the present study are also based on its role of
promoting ICD. Calreticulin treatment adjuvant to PDT results in
markedly increased levels of this protein exposed on the cell surface
by adding from the external source to that of the internal origin
already present. Evidently, the added calreticulin must become
bound to certain (as yet unknown) molecules that appear on the
surface of PDT-treated cells. This elevation of calreticulin levels on
cancer cell surface appears to enhance its potential of promoting
ICD, presumably by boosting their removal by antigen-presenting
cells through phagocytosis pathways optimized for recognition of
tumor antigens.
In summary, the present study demonstrates that externally
added calreticulin protein, which has the ability to bind to tumor
cells sustaining injury/stress from PDT treatment, can serve as an
effective adjuvant augmenting tumor control with this therapy.
Lack of such positive effect with tumors growing in immunod-
eficient mice indicates that the observed therapeutic gain with
adjuvant calreticulin entails the engagement of adaptive immune
system. The underlying mechanistic aspects remain to be uncov-
ered in more detail with studies such as tumor immune infiltrate
analysis. Based on the presented results, the hypothesis to be tested
is that the adjuvant treatment with calreticulin provides a supple-
ment DAMP material and promotes phagocytosis of PDT-treated
tumor cells enhancing the development of antitumor-immune
response (14, 22).
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